engleski

PREVALENCE AND ANTIMICROBIAL SUSCEPTIBILITY OF UREAPLASMA UREALYTICUM AND MYCOPLASMA HOMINIS IN PREGNANT WOMEN

Introduction: Mycoplasma hominis (M.hominis) and Ureaplasma urealyticum (U.urealyticum) frequently colonize the urogenital system of pregnant women. These bacteria can cause urogenital infections which are associated with an increased risk of adverse pregnancy outcomes such as miscarriage, preterm labor, stillbirth. Mycoplasmas are sensitive to antibiotics that interfere with protein synthesis on ribosomes ( tetracyclines, macrolides and aminoglycosides). However, macrolides are the drugs of choice used for pregnant women, as tetracyclines and aminoglycosides are contraindicated in pregnancy. The aim of this study was to determine the prevalence and antimicrobial susceptibility of M.hominis and U.urealyticum in pregnant women in Pozega-Slavonia County. Materials and Methods: In this retrospective study, we have selected 342 pregnant women from the hospital information system, whose cervical samples were processed in the microbiological laboratory. Identification and antimicrobial susceptibility of U.urealyticum and M.hominis were determined using a commercially available Mycoplasma IST-2 kit (BioMerieux, France) according to standard laboratory protocol. We tested seven antibiotics: doxycycline, tetracycline, azithromycin, erythromycin, clarythromycin, ciprofloxacin, ofloxacin. The results were interpreted according to CA-SFM (EUCAST 2015) protocols.Results: The overall prevalence of U.urealyticum was 36%, M. hominis only 0.3%, while the co-infection was 2%. The youngest pregnant women had 15 years and the oldest 46 years. Antimicrobial susceptibility of genital mycoplasmas was the highest to tetracycline (100%) and doxycycline (100%). Resistance to azithromycin was 35% for U.urealyticum while for M.hominis and co- infection were 100%. Resistance to clarithromycin was only 4% for U. urealyticum whereas in M. hominis was 100% and in co- infection was 67%. Resistance to erythromycin was 21% for U. urealyticum whereas in M. hominis and co- infection was 100%. Conclusion: The overall prevalence of U. urealyticum and M. hominis in pregnant women was 38.3% which is less than in other countries. In the treatment of infections caused by these microorganisms in pregnant women we recommend clarithromycin (resistance rate 4%) and erythromycin (resistance rate 21%).

Mycoplasma hominis ; Ureaplasma urealyticum

nije evidentirano